Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis

Journal of Chemotherapy

Volumn 7, Issue 2, 1995, Pages 146-152

  Beghi, G ^a   Berni, F ^a   Carratu, L ^b   Casalini, A ^d   Consigli, G ^d   D'Anto M ^c   Gioia, V ^e   Molino, A ^b   Paizis, G ^a   Vaghi, A ^a  

^a SANTA CORONA HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d “Rasori” Hospital ^*  (Italy)

^e Ospedale GF Ingrassia   (Italy)

Author keywords

Amoxicillin clavulanic acid; Antibiotics; Azalide; Azithromycin; Beta lactam; Beta lactamase inhibitor; Exacerbation of chronic bronchitis; Lower respiratory tract infections; Safety; Tolerance

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLAVULANIC ACID;

ADULT; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AZITHROMYCIN; BACTERIAL INFECTIONS; BRONCHITIS; CHRONIC DISEASE; CLAVULANIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SPUTUM;

EID: 0028929440     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.1995.7.2.146     Document Type: Article

References (27)

1. Riechek N, Lewin EG, Rhoden D, et al. Antibody responses to bacterial antigens during exacerbations of chronic bronchitis. Am Rev Resp Dis 1970; 101: 238-244.
2. Stenhouse AC. Rinovirus infection in acute exacerbations of chronic bronchitis: a controlled prospective study. Br Med J 1967; 3: 461-463.
3. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic bronchitis. Ann Intern Med 1987; 106: 196-204.
4. Legnani D. Bronchite cronica e l’asma bronchiale: le sovrainfezioni. Giorn Ital Mal Torace 1991; 45, (Suppl 4): 271-274.
5. Hoepelman AIM, Sips AP, van Helmond JLM, et al. A single-blind comparison of a three-day azithromycin and ten- day co-amoxiclav treatment of acute and lower respiratory tract infections. J Antimicrob Chemother 1993; 31: 147-152.
6. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993; 31: 153-162.
7. Balmes P, Clerc G, Dupont B, Labram C, Pariente R, Poirier R. Comparative study of azithromycin and amoxi- cillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1991; 31: 437-439.
8. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory infections. Am J Med 1991; 91 (Suppl. 3A): 31S-35S.
9. Barsic B, Schonwald S, Sagud M, Klinar I. Three days azithromycin versus ten days of cefaclor in treatment of bacterial lower respiratory tract infections. In: Einhorn J., Nord C.E., Norrby S.R. ed. Recent Advances in Chemother. Proceedings 18th Intern. Congr. Chemother. Stockholm 1993; 27/06-02/07. 1994: 24-25.
10. Daniel R and European Azithromycin Study Group: Simplified treatment of acute respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. J Int Med Res 1991; 19 (5): 373-383.
11. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25, Suppl. A: 73-82.
12. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91, Suppl. 3A: 5S-11S.
13. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25, Suppl. A: 39-47.
14. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithomycin (CP 62993), a new 15-mem- bered-ring macrolide with improved potency against gramnegative organisms. Antimicrob Agents Chemother 1987; 31, 12: 1939-1947.
15. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991; 91, Suppl. 3A: 12S-18S.
16. Neu HC. Comparative in vitro activity of the new oral macrolide azithromycin. Eur J Clin Microbiol Infect Dis 1988; 7, 4: 541-544.
17. Maskell JK, Sefton AM, Williams DJ. Comparative in vitro activity of azithromycin and erithromycin against gram positive cocci, Haemophilus influenzae and anaerobes. J Antimicrob Chemother 1990; 25, Suppl A: 19-24.
18. Edelstein PH, Edelstein MA. In vitro activity of azithromycin against clinical isolates of legionella species. Antimicrob Agents Chemother 1991; 35, 1: 180-181.
19. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10, 10: 828-833.
20. Goldstein FW, Emirian MF, Controt A, Acar JF. Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J Antimicrob Chemother 1990; 25 Suppl A: 25-28.
21. Schonwald S, Gunjaca M, Kolacny-Babic L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumoniae. J Antimicrob Chemother 1990; 25, Suppl A 123-126.
22. Widfeuer A, Laufen H, Leitold M, Zimmermann T. Comparison of the pharmacokinetics of three-day and five- day regimens of azithromycin in plasma and urine. J Antimicrob Chemother 1993; 31, Suppl A 51-56.
23. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993; 31, Suppl E 57-64.
24. Glaude RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990; 34, 6: 1056-1060.
25. Bauer AW, Kirby WMM, Sherris JC, et al. Antibiotic susceptibility testing by standardized single disk method. Am J Clin Pathol, 1966; 45: 493-496.
26. Bartlett RC. Medical microbiology: quality, cost and clinical relevance. New York: J. Wiley & Sons 1974.
27. Neu HC, Wilson APR, Gruneberg RN. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 1993; 5(2): 67-93.